主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2015, Vol. 38 ›› Issue (12): 801-805.doi: 10.3969/j.issn.1006-2157.2015.12.002

• 博士之光 • 上一篇    下一篇

降压通络方对高血压肾损害大鼠肾上腺髓质素表达的影响*

秦建国1, 韩琳2#, 王媛媛2, 高誉珊2, 张晓宇1, 郭一1, 宋林梅2, 罗燕妮1, 迟笑怡1   

  1. 1 北京中医药大学东方医院 北京 100078;
    2 北京中医药大学基础医学院
  • 收稿日期:2015-01-08 出版日期:2015-12-30 发布日期:2015-12-30
  • 通讯作者: 韩琳,女,博士,副教授,硕士生导师,E-mail:qintdtg@163.com
  • 作者简介:秦建国,男,博士,主任医师
  • 基金资助:
    *国家自然科学基金资助项目(No.811734071),北京市薪火传承郭士魁研究室项目(No.2011-SZ-A-27),北京中医药大学东方医院优才项目,北京中医药管理局双百工程金章安教授传承项目

Effects of Jiangya Tongluo Formula on adrenomedullin in rats with hypertensive nephrosclerosis*

QIN Jianguo1, HAN Lin2#, Wang Yuanyuan2, GAO Yushan2, ZHANG Xiaoyu1, GUO Yi1, SONG Linmei2, LUO Yanni1, CHI Xiaoyi1   

  1. 1 Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078;
    2 School of Preclinical Medicine, Beijing University of Chinese Medicine
  • Received:2015-01-08 Online:2015-12-30 Published:2015-12-30

摘要: 目的 观察降压通络方对高血压病肾损害大鼠肾脏肾上腺髓质素(ADM)表达的影响,探讨其对高血压肾损伤大鼠肾脏的保护作用。方法 采用16周龄自发性高血压大鼠(SHR)为研究对象,将其随机分为模型组、缬沙坦组、降压通络方组、并设正常血压大鼠(WKY)为空白对照。降压通络方组、缬沙坦组分别给予降压通络方14.2 g/(kg·d)和缬沙坦10 mg/(kg·d)灌胃治疗,模型组及正常对照组给予等量的生理盐水。观察各组大鼠在给药前、给药2周、4周、8周后血压的变化,测定大鼠24 h尿蛋白定量,同时观察肾功能及肾脏病理组织学改变,检测大鼠肾脏中ADM的蛋白含量,并与大鼠的血压进行相关性分析。结果 模型组及各治疗组大鼠血压、24 h尿蛋白、血肌酐(Scr)、尿素氮(BUN)较正常对照组明显升高,降压通络方组、缬沙坦组均明显低于模型组(P<0.01),但2个治疗组之间比较无显著性差异;模型及各治疗组大鼠肾脏ADM蛋白含量较正常对照组明显降低(P<0.01),与模型组比较,降压通络方及缬沙坦组大鼠肾脏ADM蛋白含量明显升高(P<0.01),并与大鼠的血压呈明显负相关(γ=-0.740,P<0.001),但2个治疗组之间比较无明显差异。HE染色显示降压通络方能显著改善肾小动脉及肾小球硬化,促进肾组织结构的恢复。结论 降压通络方通过上调高血压肾损害大鼠肾脏ADM的表达,扩张肾脏局部小血管,改善肾脏缺血,在保护肾脏功能方面起到重要作用。

关键词: 降压通络方, 高血压病肾损害, 肾上腺髓质素, 自发性高血压大鼠

Abstract: Objective To observe the effects of Jiangya Tongluo Formula (blood pressure-lowering collateral-unblocking formula, JYTLF) on adrenomedullin (ADM) in rats with hypertensive nephrosclerosis and to investigate its protective effect on kidney. Method Twenty-one 16-week-old spontaneous hypertensive rats (SHR) were used as subjects and randomly divided into model group (SHR group), valsartan group, and JYTLF group. Seven healthy Wistar Kyoto (WKY) rats were used as the blank control group. JYTLF group was orally given Jiangya Tongluo Formula (14.2 g/kg/d) while valsartan group received valsartan (10 mg/kg/d), both by intragastric gavage. The control group and the model group were given saline at the same dosage. Blood pressure of these rats was measured before treatment and at 2, 4, 8 weeks after treatment. 24-hour urinary albumin, kidney function parameters and histopathological changes of kidney tissue in four groups were measured as well. ADM protein levels in kidney were also measured to correlate with the blood pressure levels. Results Levels of blood pressure, 24-hour urinary albumin, serum creatine (Scr), and blood urea nitrogen (BUN) were significantly higher in the model group, valsartan group, and JYTLF group when compared with those in the blank control group. These levels in valsartan and JYTLF groups were lower than those in model group (P<0.01), yet there was no significant difference between the two treatment groups. Kidney ADM levels decreased markedly (P<0.01) in the model group, valsartan group and JYTLF group when compared with the normal control group. ADM levels in valsartan group and JYTLF group were higher than those in the model group (P<0.01) and there was an inverse correlation between ADM and blood pressure levels (γ=-0.740,P<0.001), yet no significant difference was observed between two treatment groups. HE staining showed that Jiangya Tongluo Formula significantly improved the renal arteries and glomerular sclerosis, thus promoted the recovery of kidney tissue. Conclusion Jiangya Tongluo Formula could up-regulate the level of ADM in kidneys in rats with hypertensive nephrosclerosis, dilate renal blood vessels and renal ischemia, which may play an important role in protecting renal function.

Key words: Jiangya Tongluo Formula, hypertensive nephrosclerosis, adrenomedullin, spontaneous hypertensive rat

中图分类号: 

  • R285.5